Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2019-05-31 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to furnish reports or other documents required to be made public under home country laws or exchange rules. The document includes a press release as Exhibit 99.1 dated May 29, 2019. The text does not contain detailed financial statements or substantive financial data but rather references the press release and incorporates it by reference. The document length is 2685 characters, which is relatively short and consistent with a regulatory filing or announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS), as it does not contain the full report itself but rather a filing of a press release and related information.
2019-05-31 English
GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)
Regulatory Filings Classification · 90% confidence The document is a press release dated May 29, 2019, announcing the presentation of recent results for the drug filgotinib at the European Congress of Rheumatology (EULAR 2019). It details the study names (FINCH 1, FINCH 3, EQUATOR), the nature of the data (interim results, efficacy, safety), and includes standard boilerplate language about the experimental status of the drug and forward-looking statements typical of corporate news releases. This content is not a formal regulatory filing like a 10-K, nor is it a transcript of a call (CT) or a formal earnings release (ER). It is a specific announcement about clinical trial data being presented at a medical conference. This type of announcement, which details scientific/clinical progress and often precedes a formal report or is a standalone update on R&D, fits best under the general category of Investor Information or a specific regulatory announcement. Given the options, it is a press release announcing scientific/clinical data, which is often categorized as a general Regulatory Filing (RNS) if no better fit exists, or sometimes as an Investor Presentation (IP) if it were the slides themselves. Since it is a press release announcing data presentation, and not the presentation itself, RNS is the most appropriate fallback for a non-standard, time-sensitive corporate announcement, although it strongly relates to R&D progress. However, looking closely at the definitions, this is a press release announcing clinical trial results and future presentations. It is not a formal financial report (10-K, IR, ER, MRQ). It is not a presentation (IP). It is a corporate communication about R&D progress. In many databases, such detailed clinical updates are classified under general Regulatory Filings (RNS) or sometimes as Investor Relations material. Given the options, RNS serves as the best catch-all for significant, non-standard corporate news releases that aren't explicitly covered elsewhere (like DIV, DIRS, MANG, etc.). The document length (14k chars) confirms it is substantial, not a short RPA.
2019-05-30 Dutch
GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)
Regulatory Filings Classification · 95% confidence The document is a press release dated May 29, 2019, announcing that Gilead and Galapagos will present data on their drug filgotinib at the Annual European Congress of Rheumatology (EULAR 2019). It details the specific presentations (Phase 3 FINCH 1 and FINCH 3 data) and includes forward-looking statements referencing the companies' SEC filings (like Form 10-Q for Gilead). This is not a formal regulatory filing like a 10-K, nor is it a full earnings release (ER) or a transcript (CT). It is an announcement about upcoming scientific data presentation, which falls under general investor/corporate communication. Since it is a press release announcing corporate/scientific activity rather than a specific financial report or mandatory filing, the most appropriate general category is Regulatory Filings (RNS) as a catch-all for corporate announcements that don't fit the highly specific financial report codes, although it is primarily a scientific/corporate news announcement.
2019-05-30 English
S-8 Filing
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities (warrants) to be offered under employee benefit plans. The document includes legal and regulatory disclosures, indemnification clauses, incorporation by reference of other filings, and an exhibit index. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and compliance, not a report or announcement of financial results or corporate governance changes. Therefore, it fits best under the category of Regulatory Filings (RNS).
2019-05-24 English
Minutes AGM 30 Apr 2019 - EN.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "Minutes of the annual shareholders' meeting held in Mechelen on 30 April 2019". It details the proceedings, agenda items (including approval of annual accounts, remuneration reports, director appointments, and warrant offers), and resolutions passed during a formal meeting of shareholders. This content perfectly matches the definition of an Annual General Meeting (AGM) record. Therefore, the appropriate classification is AGM-R.
2019-05-16 English
AGM 30 Apr 2019 - Minutes_D_Website_final.pdf
AGM Information Classification · 99% confidence The document is explicitly titled "Notulen van de gewone algemene vergadering gehouden te Mechelen op 30 april 2019" (Minutes of the ordinary general meeting held in Mechelen on April 30, 2019). It details the agenda, attendance, and resolutions passed during a general meeting of shareholders. This content directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although minutes are a formal record, the context of an AGM makes AGM-R the most specific and appropriate classification over a general Regulatory Filing (RNS) or Audit Report (AR).
2019-05-16 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.